Omeprazole (A2845): Technical Application in H+,K+-ATPase and Gastric Acid Secretion Research

What This Product Solves

Omeprazole, chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a potent H+,K+-ATPase inhibitor with well-characterized use in gastric acid secretion research and antiulcer activity studies. Its primary value lies in selectively inhibiting the gastric proton pump, enabling modeling of gastric acid-related disorders and mechanistic evaluation of antiulcer compounds. Unlike clinical formulations, this research-grade compound from APExBIO is optimized for in vitro and preclinical protocols, providing reproducible pharmacological blockade in experimental systems.

Researchers employ Omeprazole (A2845) for:

• Modeling peptic ulcer disease in animal or cell-based assays
• Investigating gastric acid secretion pathways and proton pump inhibition
• Validating antiulcer agent mechanisms in controlled laboratory conditions

For further procedural detail, the article "Omeprazole (A2845): Protocol Guidance for H+,K+-ATPase Research" outlines critical steps for robust experimental design, while "Optimizing Gastric Acid Secretion Research with 3-(quinolin-4-ylmethylamino)..." provides troubleshooting strategies and advanced modeling considerations.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition
  Value: IC₅₀ = 5.8 μM
  Applicability: Use as starting concentration range in enzyme inhibition assays.
  Rationale: Product dossier reports 5.8 μM as the IC₅₀ for H+,K+-ATPase, guiding dose selection for mechanistic studies.
  Source: Product dossier
• Assay: Histamine-induced gastric acid formation
  Value: IC₅₀ = 0.16 μM
  Applicability: Establishes potency in functional cell-based or tissue assays modeling acid secretion.
  Rationale: Reflects compound's efficiency in suppressing histamine-stimulated acid output.
  Source: Product dossier
• Assay: Stock solution preparation
  Value: ≥17.27 mg/mL in DMSO
  Applicability: For preparing concentrated stocks; do not use water or ethanol.
  Rationale: Omeprazole is insoluble in water and ethanol, and DMSO is required for dissolution to workable concentrations.
  Source: Product dossier
• Assay: Storage conditions
  Value: Solid form at -20°C; avoid long-term solution storage
  Applicability: For maintaining compound stability and purity during storage.
  Rationale: Omeprazole is stable as a solid at -20°C but may degrade in solution; fresh aliquoting is recommended before use.
  Source: Product dossier

Workflow Setup and QC Checklist

• Compound Handling: Upon receipt, inspect for intact packaging and blue ice presence. Immediately transfer Omeprazole to -20°C storage in solid form to preserve purity (~98%).
• Solution Preparation: Dissolve the required amount in DMSO to achieve ≥17.27 mg/mL concentration. Prepare fresh stocks before each experiment and avoid repeated freeze-thaw cycles; aliquot if necessary.
• Assay Design: For H+,K+-ATPase inhibition or gastric acid secretion research, begin with concentration series bracketing reported IC₅₀ values (e.g., 0.05–10 μM) to establish dose-response relationships.
• Control Selection: Include both vehicle (DMSO only) and positive control wells. Account for DMSO concentrations in all conditions to prevent solvent artifacts.
• Quality Control: Record batch number and preparation date. Confirm compound solubility and lack of precipitation in assay buffer prior to use.
• Documentation: Capture all preparation and handling steps in laboratory records to facilitate troubleshooting and reproducibility.

Common Failure Modes and Fixes

• Poor Solubility: If undissolved particulates are present after DMSO addition, gently vortex and briefly sonicate. Do not attempt to dissolve in water or ethanol; this will result in incomplete solubilization.
• Loss of Activity: Degradation may occur if Omeprazole is stored as a solution for extended periods. Always prepare fresh solutions and store as solid at -20°C between uses.
• Inconsistent Assay Results: Variability may arise from inaccurate dilution or solvent effects. Standardize pipetting technique and maintain DMSO concentrations below cytotoxic thresholds (typically ≤0.1% v/v in final assay conditions, per standard cell culture practice).
• Precipitation in Assay Buffer: If visible precipitation occurs upon dilution, reduce stock concentration, warm gently, or increase mixing. Confirm compatibility of assay buffer with residual DMSO.

Scope and Limitations

• Omeprazole (A2845) is strictly intended for research use; it is not validated for diagnostic or therapeutic application in humans or animals.
• The compound’s activity as an H+,K+-ATPase inhibitor is well established for in vitro and preclinical models of gastric acid-related disorders, but translation to other enzyme systems or in vivo models outside the gastric context is not supported by the supplied data.
• Due to its water and ethanol insolubility, assays requiring aqueous delivery must utilize DMSO as solvent, with careful control of final solvent concentration.
• Long-term storage of solutions, or improper temperature handling, can compromise compound stability and reproducibility of results.

Conclusion

Omeprazole (A2845) offers a robust, well-characterized tool for mechanistic studies involving gastric acid secretion and antiulcer activity. Proper handling, storage, and preparation—guided by the manufacturer’s dossier and allied internal resources—are essential for reproducible results in research workflows. By adhering to established protocol parameters and addressing common pitfalls, researchers can maximize the reliability and interpretability of experimental findings involving this H+,K+-ATPase inhibitor from APExBIO.